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Abstract 
Throughout the long history of virus-host co-evolution, viruses have developed delicate strategies 
to facilitate their invasion and replication of their genome, while silencing the host immune 
responses through various mechanisms. The systematic characterization of viral protein-host 
interactions would yield invaluable information in the understanding of viral invasion/evasion, 
diagnosis and therapeutic treatment of a viral infection, and mechanisms of host biology. With 
more than 2,000 viral genomes sequenced, only a small percent of them are well investigated. The 
access of these viral open reading frames (ORFs) in a flexible cloning format would greatly facilitate 
both in vitro and in vivo virus-host interaction studies. However, the overall progress of viral ORF 
cloning has been slow. To facilitate viral studies, we are releasing the initiation of our panviral 
proteome collection of 2,035 ORF clones from 830 viral genes in the Gateway® recombinational 
cloning system. Here, we demonstrate several uses of our viral collection including highly efficient 
production of viral proteins using human cell-free expression system in vitro, global identification of 
host targets for rubella virus using Nucleic Acid Programmable Protein Arrays (NAPPA) 
containing 10,000 unique human proteins, and detection of host serological responses using 
micro-fluidic multiplexed immunoassays. The studies presented here begin to elucidate host-viral 
protein interactions with our systemic utilization of viral ORFs, high-throughput cloning, and 
proteomic technologies. These valuable plasmid resources will be available to the research 
community to enable continued viral functional studies. 
Key words: Panviral proteome, ORFeome, Gateway® cloning, Gene synthesis, Virus-host 
interactions, Nucleic Acid Programmable Protein Arrays (NAPPA). 
Introduction 
With the rapid progression of high-throughput 
(HT) -omic technologies (e.g., genomics, 
transcriptomics and proteomics), biological 
information has exploded over the past decade. These 
HT approaches allow scientific investigations to shift 
from traditional reductionism to systems biology 
approaches to study complex interactions in 
biological systems with a holistic perspective [1]. As 
simple intracellular organisms, viruses must hijack 
host factors to survive and propagate at multi-stages 
of their life cycles in the host. Viruses have developed 
a variety of delicate strategies to facilitate their 
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invasion and replication/transcription of their 
genomes, while at the same time silencing host 
immune responses by manipulating host proteins and 
cellular processes. The systematic characterization of 
the viral proteome-host interactions, and the 
identification of new host targets, would be 
invaluable in the understanding of viral invasion and 
replication mechanisms in infectious diseases, 
autoimmune diseases, and cancer [2]. The findings 
from these studies will greatly facilitate the detection 
of viral infection and progression, antiviral drug 
discovery, and therapeutic treatment [3-5].  
Through a profound effort from the ORFeome 
Collaboration, a large set of sequence-verified open 
reading frame (ORF) clone collections (bacteria, yeast, 
mouse, human) have been constructed and are 
accessible to the research community [6-14]. 
Interestingly, of the 2,000 viral genomes that have 
been sequenced, only a small fraction of viral 
ORFeome plasmids have been constructed, and the 
molecular mechanism of most of virus-host 
interactions is largely unknown [2]. Pellet et al. 
pioneered the ViralORFeome 1.0 
(http://pbildb1.univ-lyon1.fr/viralorfeome/index.p
hp), an open-access database and management 
system that provides an integrated set of 
bioinformatics tools enabling the potential capture of 
viral ORFs in the Gateway® recombinational cloning 
system. With the ViralORFeome database, Pellet et al. 
collected 545 ORF clones from ~238 viral genes in 
Gateway® entry vectors (pDONR207 or pDONR223). 
In addition, this study demonstrated the phenotypic 
expression of 67 viral genes transfected in HEK-293T 
cells [15]. Unfortunately, the overall progress of viral 
cloning has not progressed much beyond this due to 
the high cost of HT cloning and the difficulty in 
managing a large repository in a general lab [2, 15, 16].  
Since the establishment of our laboratory and the 
DNASU Repository at Arizona State University, we 
have devoted significant effort in the HT cloning, 
construction, and maintenance of large DNA 
repositories (http://dnasu.org) [17, 18]. We have 
successfully created tens of thousands of 
sequence-verified ORFs in Gateway® recombination 
system, ranging from human to numerous pathogens 
and model organisms, such as S. cerevisiae, P. 
aeruginosa, F. tularensis, V. cholerae and Y. pestis [17-25]. 
The high flexibility of Gateway® system allows 
researchers to rapidly transfer these collections into 
any compatible expression vectors that fit their 
biological studies [26-36]. For example, using the S. 
cerevisiae plasmid collection, Zhu et al. purified 89 
known and predicted S. cerevisiae transcription factor 
proteins, and profiled their DNA binding sites using 
ChIP-chip. More than 2.3 million gapped and 
ungapped 8-bp oligo sequences were identified, 
which allowed the re-annotation of in vivo TF binding 
targets, and examination of TFs' potential effects on 
gene expression in about 1700 environmental and 
cellular conditions [23, 34]. Cooper et al. executed a 
genome-wide screen of 3,000 over-expressed yeast 
genes for the enhancers and suppressors of 
alpha-synuclein (αSyn). The misfolding of αSyn is 
associated with devastating neurodegenerative 
disorders such as Parkinson’s disease (PD). 34 and 20 
genes were identified to suppress and enhance αSyn 
toxicity, respectively. Rab1, the mammalian YPT1 
homolog, was found to protect against αSyn-induced 
dopaminergic neuron loss in PD animal models [35]. 
We constructed human and pathogen Nucleic Acid 
Programmable Protein Arrays (NAPPA), with which 
we executed wide proteomics studies to find the 
antibody biomarkers that have potential value in the 
early detection of cancers, diabetes, autoimmune, and 
infectious diseases [26-33].  
In this project, we plan to generate a plasmid 
collection that encodes all important human disease 
related viral proteins (~6,000). The aim of our panviral 
proteome is to discover and characterize virus-host 
interactions and determine the association of these 
viral proteins with various human diseases. Similar to 
our human and pathogen collections, we will 
distribute these viral ORF constructs to the research 
community though DNASU (http://dnasu.org) [11], 
including the initial collection described in this paper 
containing 2,035 ORF clones in Gateway® entry 
vector (pDNOR221) and mammalian cell-free 
expression vectors (Table 1). To illustrate the 
applications of this collection, we characterized the 
expression of ORF clones from three viral genomes 
utilizing human HeLa cell lysate-based cell-free 
expression system, western blot, and in-gel 
fluorescence. In addition, we studied rubella 
virus-host interactions using NAPPA arrays 
displaying 10,000 unique human proteins. We also 
analyzed the host serological response to 
coxsackievirus antigens using micro-fluidic 
multiplexed immunoassays. The explorations of our 
viral clone collection showed the highly efficient 
cell-free production of viral ORF proteins in vitro, 
identification of novel host-viral protein interactions, 
and a demonstration of how immune-dominant viral 
antigens could be used in the future for target drug 
development and detection of viral pathogen 
infection. 
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Table 1. List of viral ORF clones that have been collected. 
Name Abbre. Family Entry vector Mammalian cell-free  
expression vectors Closed Fusion 
Epstein–Barr virus EBV Herpesvirinae 73 89 89 
Hepatitis B Virus HBV Hepadnaviridae  7 7 
Human papillomaviruses, type5 HPV5 Picobirnaviridae - 4 4 
Human papillomaviruses, type6 HPV6 Picobirnaviridae - 5 5 
Human papillomaviruses, type8 HPV8 Picobirnaviridae - 3 3 
Human papillomaviruses, type11 HPV11 Picobirnaviridae - 5 5 
Human papillomaviruses, type16 HPV16 Picobirnaviridae - 3 8 
Human papillomaviruses, type18 HPV18 Picobirnaviridae - 4 8 
Human papillomaviruses , type33 HPV33 Picobirnaviridae - 4 4 
Kaposi’s sarcoma-associated herpesvirus KSHV Herpesviridae 67 67 67 
Human cytomegalovirus HCMV Herpesvirinae - 165 165 
Herpes simplex virus type 1 HSV1 Herpesviridae 94 94 94 
Adenovirus  Adenoviridae - 16 16 
Simian virus 40 SV40 Polyomaviridae 6 6 6 
Varicella-zoster virus VZV Herpesviridae 66 84 94 
Vaccinia VACV Poxviridae  167 167 
Human endogenous retrovirus K HERK Retroviridea 4 4 4 
Influenza A virus, H1N1  Orthomyxoviridae - 10 10 
Influenza A virus, H3N2  Orthomyxoviridae - 10 10 
Chikungunya virus CHIKV Togaviridae 9 9 9 
Sindbis virus SINV Togaviridae 9 9 9 
Semliki Forest virus SFV Togaviridae 9 9 9 
Yellow fever virus YFV Flaviviridae 11 11 11 
Tioman virus  Paramyxoviridae 3 3 3 
Measles virus MeV Paramyxoviridae 5 5 5 
Coxsackievirus  Picornaviridae - 12 12 
Mumps virus MuV Paramyxoviridae - 8 8 
Rubella virus RUBV Togaviridae - 5 5 
Rotavirus A RV-A Reoviridae - 12 12 
Number   356 830 849 
Total number    2035  
 
 
Materials and Methods 
HT 2-Step PCR based cloning 
We performed the HT 2-step PCR cloning as 
previously described [20]. Briefly, the reference 
sequences of viral ORFs were uploaded into our 
FLEXGene Laboratory information management 
system (LIMS) (http://flex.asu.edu/FLEX). The gene 
specific primers were designed by using a 
nearest-neighbor algorithm, with each primer 
containing a gene specific region and partial attB site. 
Universal primers were employed to provide the 
remaining full length attB site and further 
amplification of the target gene ORF. The start codon 
was normalized to ATG. The fusion and closed 
versions of the entry clones were created with and 
without removal of stop codon, respectively. 
Two-step PCR amplifications were performed in 
96-well PCR plate using Tm of 60oC with Veriti® 
Thermal Cycler (Life Technologies, Grand Island, 
NY). The 2nd PCR products were examined using E 
Gel® Electrophoresis System (Life Technologies, 
Grand Island, NY) (Figure 2A). Lastly, the PCR 
product was purified using PCR clean-up kit 
(MACHEREY-NAGEL, Bethlehem, PA).  
De novo gene synthesis 
Gene design 
First, attB1 (GGGGACAAGTTTGTACAAAAAA
GCAGGCTCCACC) and the converse complemen-
tary oligo of attB2 (GACCCAGCTTTCTTGTACAAA
GTGGTCCCC) were added to both ends of ORF ref-
erence sequences. The oligos with less than 60 base 
pairs (bp) were designed using oligoDesign3.0 
(http://54.235.254.95/cgi-bin/gd/gdOlapDes.cgi), 
which can be separated into several blocks according 
to the length of target sequence [37, 38]. The oligos 
were ordered from Integrated DNA Technologies 
(Coralville, IA).  
Preparation of oligos and primers 
All oligos were diluted into the stock 
concentration of 30 µM. The Template Oligo Mix 
(TOM1) was prepared by mixing 5 µL of inner oligos 
of each block with appropriate nuclease-free H2O to 
the final concentration of 2.5 µM. Primer Oligo Mix 
(POM1) was prepared by mixing 10 µL of the first and 
last oligos of each block with appropriate H2O to the 
final concentration of 10 µM. Primer Oligo Mix 
(POM2) was prepared by mixing 10 µL of the first and 
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last oligo at the end of target ORF reference sequence 
with appropriate H2O to the final concentration of 10 
µM. Gateway® universal forward and reverse 
primers (GUPs) were prepared at 10 µM[39]. 
Gene synthesis 
For the viral ORFs with longer sequences 
(>700bp), the oligos need to be separated into mul-
ti-blocks by Gene Design 3.0, and undergo several 
assembly/amplification cycles to synthesize 
full-length reference sequence, e.g. HBV polymerase 
(Figure 2B). For the assembly of short oligos (≤ 60bp), 
each block was performed in a 50 µL reaction con-
taining 1U iProof polymerase (BioRad, Hercules, CA) 
and 2.5 µL of a 250 µM TOM1 oligo mix. The PCR 
reaction was executed by starting at 98oC for 4 minute 
(min), followed by 25 cycles of 30 seconds (s) at 98oC 
for denaturation, 45s at 59oC for annealing, and 45s at 
72oC for elongation. The amplification reaction was 
performed in a 50 µL PCR mix containing 1U iProof 
polymerase (Hercules, CA), 2 µL of assembled prod-
uct, and 5 µL of POM1. The PCR reaction was exe-
cuted with the same conditions as stated above, ex-
cept 30 cycles was used. The amplified PCR products 
were ran and examined on an agarose gel with Eth-
idium Bromide and Bioline Hyperladder I (Bioline, 
Taunton, MA). Once the final assembled oligos were 
confirmed, they were purified using QIAquick Gel 
Extraction Kit (QIAGEN, Valencia, CA), and quanti-
tated using a Nanodrop spectrophotometer (Wil-
mington, DE).  
The assembly of seven blocks of HBV 
polymerase ORF sequence was performed in a 50 µL 
reaction containing 1U iProof polymerase and 50 ng 
of previously annealed oligos from each block. The 
second assembly PCR was performed the same as the 
first assembly reaction, but with a 1min elongation 
step. The second amplification reaction was 
performed in a 50 µL reaction containing 1 U iProof 
polymerase, 2 µL of previous assembled PCR product, 
and 5 µL of POM2 or UOP. The PCR was run under 
the same conditions as the first amplification reaction, 
but with a 2min elongation step. Once the full-length 
ORF reference sequence was synthesized, it was 
purified and the concentration was quantitated using 
a Nanodrop spectrophotometer (Figure 2B).  
Construction of viral entry & expression clones  
The procedure for the construction of entry and 
expression clones using the Gateway® system has 
been well described previously [14, 20, 23, 40]. Briefly, 
all purified PCR products and synthesized ORF 
sequences with attB1 and attB2 sites were cloned into 
a Gateway® entry vector (pDONR221) using BP 
Clonase (Life Technologies, Grand Island, NY). The 
clones were colony selected from agar plates and the 
ORF inserts were sequenced verified using our 
Automatic Clone Evaluation (ACE) software. For 
clones to be accepted in our viral gene plasmid 
collection, they must not contain truncations, 
frameshifts, or more than one amino acid change 
when compared to the reference sequence. In 
addition, any nucleotide change in the sequences of 
att-sites was also not accepted because it may cause 
failure of BP or LR reactions [20, 21].  
To construct the collection of expression clones, 
sequence verified viral ORFs in entry vectors were 
transferred into mammalian cell-free expression 
vectors (pANT7_cGST, pJFT7_nHalo or pJFT7_cHalo) 
using LR Clonase (Life Technologies, Grand Island, 
NY). All solution transfers were executed by the 
Biomek FX automation workstation, and each cloning 
step was assigned a specific barcode which is tracked 
by the FLEXGene database throughout the cloning 
process. 
Identification of host targets for rubella virus 
using NAPPA arrays 
Five NAPPA arrays containing 10,000 purified 
human cDNA plasmids were printed as previously 
described (~2,000 ORFs/slide) [41]. To prepare 
NAPPA protein arrays, the slide was blocked with 
Superblock solution (Pierce, Rockford, IL) for 1hour 
(hr) at room temperature. The slide was then covered 
with a hybridization chamber and 160 µL of human 
HeLa cell lysate-based cell-free expression system 
(Thermo scientific, Rockford, IL) was injected into the 
chamber. The cell-free expression was performed at 
30oC for 1.5 hrs, and then incubated at 15oC for 0.5 h. 
After briefly washing with PBST (PBS, 0.2%Tween 
20), the resulting NAPPA protein array was blocked 
with cold PPI blocking buffer (1×PBS, 1%Tween 20 
and 1% BSA, pH7.4) for 2 hrs at 4oC. In parallel, the 
rubella viral ORFeome proteins with C-terminal Halo 
tag (E1, E2, P90, capsid, and the mix of 150N and 
150C) were produced in 170 µL human HeLa cell 
lysate-based cell-free expression system for 2 hrs at 
30oC with 100 ng/µL of DNA.  
To identify the host targets of rubella virus using 
our NAPPA arrays, the NAPPA human 10K arrays 
were incubated with the expressed rubella viral 
proteins in HeLa cell lysates for 16 hrs at 4oC. After 
washing three times with PPI wash buffer (PBS, 5 mM 
MgCl2, 0.5% Tween20, 1% BSA and 0.5% DTT, pH7.4), 
the protein-protein complexes formed on the NAPPA 
arrays were detected using 12.5 µM Alexa 660 
conjugated Halo-ligand (Promega, Madison, WI) and 
incubated for 2hrs at 4oC. The fluorescent images were 
obtained with a Tecan’s PowerScanner (Männedorf, 
Switzerland). The fluorescent signal intensity was 
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quantitated using Array-Pro Analyzer (Media 
Cybernetics, Bethesda, MD). 
Statistical analysis 
Prior to the statistical analysis, we examined all 
fluorescent microarray images for the spot shape, 
dust, and non-specific binding, in order to remove 
false positive signals. We then normalized the raw 
signal intensity of all spots to decrease the 
background variations from slide to slide. 
Normalization was performed by subtracting the 
background signals from non-specific binding of 
query proteins or Alexa660 labeled Halo ligand, 
which was estimated by the first quartile of the 
printing buffer-only control. Next, we calculated the 
normalized value using the raw signal intensity of 
each spot divided by the median 
background-adjusted value of all features on the 
array. Finally, we calculated the Z-score of each 
protein that was used for the target selection. 
The selection of host target candidates of rubella 
virus was based on the following criteria: (1) Z-score ≥ 
3, (2) Z-score ratio of query protein to Halo negative 
control ≥ 2, and (3) the targets have to meet previous 
criteria in two independent experiments.  
Bioinformatics analysis 
The protein annotation was performed with The 
UniProt (Universal Protein Resource) databases and 
PANTHER (Protein ANalysis THrough Evolutionary 
Relationships) Classification System. The rubella 
virus-host interaction network was built using 
Cytoscape (v2.6.3, available in http://www.cytoscap
e.org). 
Co-localization verification of rubella virus 
capsid with host targets identified from 
NAPPA screens 
The rubella virus capsid and its identified host 
targets were cloned into pCS Cherry DEST (Addgene) 
and pcDNATM6.2/N-EmGFP/YFP-DEST (Life Tech-
nologies) vectors, respectively, using LR recombinant 
reactions. HeLa cells were transiently co-transfected 
with GFP-host targets and mCherry-capsid for 20 hrs. 
The cells were then fixed in 4% paraformaldehyde 
PBS and imaged using Zeiss LSM 510 inverted fluo-
rescence confocal microscope (Zeiss) (100x objective) 
and images analyzed on ImageJ software.  
Serological analysis of coxsackievirus proteins 
using micro-fluidic multiplexed immunoassays 
The micro-fluidic antigen channels were 
fabricated by covering an aminosilane coated glass 
slide with a customized PDMS mold embedded with 
13 micro-channels. The PDMS mold was prepared by 
soft-lithography as previous descried (Figure 6A) 
[42]. The antigen coating of each channel was 
performed by injection of 5 µL expressed 
coxsackievirus proteins in human HeLa cell 
lysate-based cell-free expression system and 
incubated for 1h at room temperature. After washing 
three times with 0.2% PBST, the PDMS mold was 
removed and the antigen coated slide was blocked 
with 5% milk for 1 hr. The reaction channels were 
prepared by applying a new set of PDMS 
micro-fluidic channels that lay vertical to the antigen 
strips formed on the slide surface. In each reaction 
channel, the immobilized antigens were detected with 
an anti-Halo antibody and Alexa555 labeled goat 
anti-chicken IgG antibody (Life Technologies, Grand 
Island, NY) (Figure 6A and 6B). 
The sera samples from human subjects were 
employed under the approval of IRB, with the age of 
subjects ranging from two to thirty-one years old. To 
test the serological response of the subjects, the sera 
were diluted 10 fold in the mix of E.coli and HeLa 
lysates, and incubated for 3 hrs. Then 5 µL of each 
diluted serum was injected into each reaction channel 
in duplicate. After a 1 hr incubation, the reaction 
channels were removed and the serological antibodies 
were captured by the antigens, and detected with 
Alexa647 labeled anti-human IgG secondary antibody 
(Jackson Immunotech, West Grove, PA). The resulting 
slide was scanned using Tecan microarray scanner, 
and the signal was quantitated in the same manner as 
the NAPPA arrays. The two-way non-hierarchical 
cluster analysis and the generation of heat map were 
performed using TM4: Microarray Software Suite 
(http://www.tm4.org/) based on complete linkage 
clustering method [43, 44]. 
Validation of coxsackievirus 
immune-dominant antigens using 
RAPID-ELISA 
The immune-dominant antigens (VP0 and VP1) 
were further tested in duplicate with the same sera 
samples using RAPID-ELISA as previously described 
[33]. The VP0 and VP1 proteins were produced as 
described above. The signals of each antigen were 
calculated by subtracting out the background noise 
produced by serum antibodies in the well without 
viral proteins from the original read.  
Results 
Construction of viral clones 
We have developed a pipeline consisting of 
enterprise-class software and databases (FLEXGene 
LIMS and ACE) that are integrated with 
state-of-the-art robotics, including a DNA Factory 
(High-Res BioSolutions), BioMek FX liquid handler, 
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and freezer storage system (Brooks Universal 
Biostore) [10, 17, 18, 45-48]. The streamlined 
integration of these systems has allowed us to manage 
our HT cloning projects, the DNASU plasmid 
repository, as well as millions of transactions in a 
seamless fashion (Figure 1A). 
To construct our viral gene collection, we created 
a reference sequence library of viral genes down-
loaded from NCBI (http://www.ncbi.nlm. 
nih.gov/pubmed/) or ViralORFeome (http://pbildb
1.univ-lyon1.fr/viralorfeome/index.php), and up-
loaded these reference sequences into our FLEXGene 
database (Figure 1A). FLEXGene enables us to track 
every construct during all stages of the cloning pipe-
line and storage. To capture these viral ORFs using 
the Gateway® cloning system, we employed two ap-
proaches: 1) HT 2-step PCR-based cloning and 2) de 
novo gene synthesis (Figure 1). The first approach has 
been frequently utilized in our lab over the past dec-
ade, and is used to clone the majority of viral genes 
with templates available [21, 23, 25, 40, 49-51] (Figure 
1B). A representative image of 2-step PCR results is 
shown in Figure 2A.  
 
Figure 1. High-throughput viral gene cloning and repository construction. (A) The pipeline of high-throughput viral gene cloning, repository management and clone distribution. 
(B) The strategies of viral gene cloning and repository construction.  
 
Figure 2. The representative images of viral gene cloning by 2-step PCR and de novo gene synthesis. (A) Examination of the 2nd PCR products from PCR-based cloning in E-gel. 
Here, 72 HSV1 ORFs amplified from their templates are shown as 9 columns × 8 rows. (B) Synthesis of HBV polymerase ORF using gene synthesis. The total 84 oligos 
(~60bp/oligo) were designed and automatically allocated into seven blocks by Gene Design 3.0. The oligos before (~60 bp/oligo) and after assembly (~400 bp/block) are shown 
at their expected sizes in an agarose gel. These assembled blocks were further annealed into a full-length HBV polymerase with the size of 2592bp, including attB sites. 
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Figure 3. Panviral proteome has the largest viral ORF clone collection to date. (A) 
Comparison of the number of viral ORF clones shared by panviral proteome and 
viralORFeome collections. (B) Examination of the expression of HCMV ORFeome 
clones from panviral proteome collection using western blot. The detection of 
GST-protein was performed using mouse anti-GST antibody and HRP labeled sheep 
anti-mouse IgG antibody. The band of expressed proteins at their expected sizes was 
visually inspected and the results is listed in Additional file 1: Table S1.  
However, the transcription of a small percentage 
of viral genes naturally contains frameshifts and 
stutters, which will not produce natural gene 
products when used in common experimental 
systems. These viral ORFs have multi-fragments with 
various lengths at different locations in their genomes, 
and cannot be simply amplified by the standard 
2-step PCR based cloning. In addition, there are also 
some viruses whose complete templates are not easily 
acquired because of the regulatory restrictions, high 
contagious risk, etc. To address these issues, we 
utilized de novo gene synthesis as an alternative 
approach to produce the viral ORF according to their 
documented reference sequences (Figure 1). First, we 
designed a series of oligos (≤ 60bp) with chunk 
overlaps of 20bp for the target viral ORF using 
oligoDesign3.0 [38]. The attB1 and reverse 
complementary of attB2 were added to the 5’ end of 
the first oligo and at the end of the last oligo, 
respectively. Depending on the length of target 
sequence and user definition, the oligos can be 
allocated into multi-blocks. The oligos in each block 
were assembled and then amplified using 
assembly/amplification PCR (Materials and 
Methods). Several assembly/amplification cycles are 
necessary to produce the full-length viral ORFs (e.g., 
HBV polymerase). Each PCR product was ran on an 
agarose gel and examined to confirm successful 
synthesis (Figure 2B). After obtaining the complete 
ORF sequence, including the attB sites, the insert (i.e., 
ORF) can then be transferred into a Gateway® entry 
vector using the BP reaction. Next, the clones were 
colony selected from agar plates and the inserts were 
sequenced verified. The viral gene’ s expected 
(reference) sequence was compared to its actual 
sequence using ACE [46], and each discrepancy (e.g., 
silent or missense mutations, inframe or frameshift 
insertions or deletions) was recorded. Only insert 
sequences that passed our defined criteria were 
accepted into our panviral plasmid collection 
(Materials and Methods) [20, 21]. With these 
approaches, we have successfully cloned 830 viral 
genes into the Gateway® entry vector and three 
mammalian expression vectors (pANT7_cGST, 
pJFT7_nHalo or pJFT7_cHalo) to create a total of 2,035 
ORF clones (Table 1). In addition, we compared the 
ViralORFeome collection to ours, and found 65 genes 
in common (Figure 3A).  
To demonstrate the applications of our panviral 
proteome collection, we utilized three viral clone sets 
to validate protein expression, examine virus-host 
interactions, and monitor detection of the host 
antibody response to coxsackievirus antigens. 
Human cytomegalovirus (HCMV) ORFeome 
expression 
In addition to sequence verifying all clones, we 
sought to demonstrate the production of protein of 
the correct size from a subset of these clones. We 
selected HCMV, which has a relatively large viral 
genome containing 165 ORFs, and transferred the 
ORFs to a mammalian cell-free expression vector 
(pANT7_cGST). The HCMV ORFeome was expressed 
in vitro using a human HeLa cell lysate-based cell-free 
expression system, the proteins were ran on a 
SDS-PAGE, and the proteins were transferred onto a 
nitrocellulose membrane. Each expressed protein has 
a C-terminal GST tag, and thus can be detected using 
a monoclonal mouse anti-GST antibody and 
HRP-labeled sheep anti-mouse IgG secondary 
antibody (Additional file 1: Supplementary 
methods). A representative image of western blot 
detection is shown in Figure 3B. By using visual 
inspection, most proteins showed a band on the 
nitrocellulose membrane at the expected locations of 
their molecular weight (Additional file 1: Table S1). 
These results indicate that all proteins from core and 
tegument classes, and most proteins from other 
classes (capsid, secreted, envelop and membrane) as 
well, were successfully expressed and detected using 
anti-GST antibody. We failed to detect protein for six 
of the 165 proteins for reasons that are not clear at this 
time.  
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As an alternative method for testing protein ex-
pression, we tested the expression of rubella viral 
ORFeome and coxsackievirus ORFs using in-gel flu-
orescence, in which the newly expressed protein of 
interest is covalently linked to a fluorescent tag (Ad-
ditional file 1: Supplementary methods). The results 
indicate that all ORFs from these two viruses were 
successfully expressed and detected with 
Alexa660-labeled Halo-ligand (Additional file 1: Fig-
ure S1 and Figure S3). In total we tested 182 proteins 
using one of these two methods, and 96.7% were de-
tected at the correct size and at a level exceeding the 
background. 
Rubella virus – host interactions 
Rubella virus has a small genome composed of 
single stranded (ss+) RNA that produces only five 
proteins (E1, E2, capsid, P90 and P150). To demon-
strate the use of our panviral proteome collection in 
the study of virus-host interactions, we performed an 
unbiased screening of potential host targets for ru-
bella viral proteins using NAPPA arrays displaying 
10,000 unique human proteins. NAPPA is an ad-
vanced cell-free protein array with high-density and 
wide screening ability [52, 53]. More than 2,300 cDNA 
constructs are printed onto an aminosiliane coated 
slide and are transcribed/translated in situ at the time 
of experimentation using a mammalian cell-free ex-
pression system. The expressed proteins are cap-
tured/displayed with high affinity and specificity by 
an anchored anti-tag antibody printed together with 
the plasmid cDNA. NAPPA has been extensively 
used for applications such as antibody characteriza-
tion, biomarker discovery, and detection of pro-
tein-protein interactions [26, 52-54].  
The NAPPA protein arrays were probed with 
each viral protein bearing an N-terminal Halo tag that 
can be readily detected using fluorescein labeled Halo 
ligand if it binds to the host protein on the arrays 
(Additional file 1: Figure S1). A representative image 
of NAPPA screening is shown in Figure 4A. The im-
age indicates that C1QBP/p32, a known host target of 
capsid [55], produced a more specific and bright flu-
orescence spot compared to neighboring proteins and 
Halo protein alone as a negative control. To select 
additional host target candidates, we employed the 
following criteria: (1) Z-score ≥ 3, (2) Z-score ratio of 
query to negative control ≥ 2, and (3) the targets 
should meet the previous two criteria in two inde-
pendent experiments (Materials and Methods). Us-
ing these parameters as a cut-off, a total of 56 host 
proteins were identified as candidate targets of ru-
bella viral proteins (Table 3 and Figure 4). Fourteen 
host proteins were further selected based on their 
Z-score and biological relevance and validated using 
an independent in vitro bead based pull-down assay 
(Additional file 1: Supplementary methods). Among 
them, six viral proteins (C1QBP, CHCHD2, ZnT8, 
GPR1, Rab25 and Arl8A) were confirmed using in 
vitro based pull-down assays (Figure 4C). In addition, 
we transiently co-transfected HeLa cells with the 
mCherry tagged capsid and four GFP tagged host 
targets for 20 hrs, and imaged the intracellular locali-
zation of both constructs using confocal microscopy. 
Besides the known binding protein of C1QBP[55], we 
found three novel host proteins,CHCHD2, DUSP26 
and NKFB1, were also co-localized with the capsid in 
HeLa cells (Figure 5). 
 
Table 2. Compare the PCR-based cloning and de novo gene synthesis. 
 PCR-based cloning De novo gene synthesis 
Target viral gene With template Without template or the viral ORF reference sequence is not contiguous in the genome 
Safety requirement High Low 
Throughput High Low 
Procedure 2-step PCRs Depending on the length of target ORF, and may need multi-assembly/amplification cycles 
Time ~ 6 hours ~ 6 hours /cycle 
Cost Low High, but can be significantly alleviated by synthesizing oligos in the lab 
 
Table 3. List of host target candidates for rubella virus identified from NAPPA arrays. 
No. Host 
protein 
Gene ID Description Protein class Cellular location Z-score 
Halo Query 
E1 targets       
1 ZnT8 169026 Zinc transporter 8 Transporter Cell membrane 0.3 6.6 
2 CCT8L2 150160 Putative T-complex protein 1 subunit theta-like 2 Chaperonin Cytoplasm -0.2 6.3 
3 LRRC58 116064 Leucine-rich repeat-containing protein 58 Growth factor receptor n.a. -0.4 4.9 
4 GPR62 118442 Probable G-protein coupled receptor 62 G-protein coupled receptor Cell membrane 0.4 4.7 
5 MEIS2 4212 Homeobox protein Meis Homeobox transcription factor Nucleus 0.5 4.6 
6 ZSCAN5A 79149 Zinc finger and SCAN domain-containing protein 5A KRAB box transcription factor Nucleus -0.1 3.8 
7 BANK1 55024 B-cell scaffold protein with ankyrin repeats n.a. n.a. 0.3 3.5 
8 GPR1 2825 G-protein coupled receptor 1 G-protein coupled receptor Membrane -0.5 3.5 
E2 targets       
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No. Host 
protein 
Gene ID Description Protein class Cellular location Z-score 
Halo Query 
9 ANXA11 311 Annexin A11 Transfer/carrier protein Cytoplasm; Melanosome; Nucleus  0.9 9.4 
10 FAM84A 151354 Protein FAM84A Acyltransferase n.a. -0.4 7.8 
11 RAB25 57111 Ras-related protein Rab-25 Small GTPase Cell membrane; Lipid-anchor; Cyto-
plasmic side 
0.2 5.4 
12 RHOJ 57381 Rho-related GTP-binding protein RhoJ Small GTPase Cell membrane; Lipid-anchor; Cyto-
plasmic side 
-0.2 5.3 
13 SMARCC1 6599 SWI/SNF complex subunit SMARCC1 Transcription cofactor Nucleus 0.2 5.0 
14 BMPR1A 657 Bone morphogenetic protein receptor type-1A Serine/threonine protein kinase 
receptor 
Membrane 0.6 4.5 
15 STAM2 10254 Signal transducing adapter molecule 2 Serine/threonine protein kinase 
receptor 
Cytoplasm -0.1 4.3 
16 RNPEP 6051 Aminopeptidase B Transporter, Membrane traffic 
protein 
Secreted -0.3 3.7 
17 MGAT1 4245 Protein O-linked-mannose be-
ta-1,2-N-acetylglucosaminyltransferase 1 
Glycosyltransferase Golgi apparatus membrane 0.1 3.7 
18 TCEB3 6924 Transcription elongation factor B polypeptide 3 Transcription factor Nucleus -0.7 3.5 
19 GNAZ 2781 Guanine nucleotide-binding protein G(z) subunit alpha Heterotrimeric G-protein Membrane; Lipid-anchor 0.5 3.4 
P90 targets       
20 TMEM106
B 
54664 Transmembrane protein 106B n.a. Late endosome membrane -0.1 7.7 
21 LCE2B 26239 Late cornified envelope protein 2B Structural protein n.a. -0.2 4.4 
22 GPR27 2850 Probable G-protein coupled receptor 27 G-protein coupled receptor  Membrane 0.4 3.2 
Capsid targets       
23 ASPSCR1 79058 Tether containing UBX domain for GLUT4 n.a. Endomembrane system 0.3 7.9 
24 PQLC3 130814 PQ-loop repeat-containing protein 3 n.a. n.a. 0.3 7.1 
25 PPP2R5D 5528 Serine/threonine-protein phosphatase 2A 56 kDa regu-
latory subunit delta isoform 
Protein phosphatase Cytoplasm; Nucleus -0.5 5.4 
26 HIST1H2A
D 
3013 Histone H2A type 1-D n.a. Nucleus; Chromosome 0.2 4.5 
27 RSF1 51773 Remodeling and spacing factor 1 Acetyltransferase, Transcription 
factor 
Nucleus 0.0 4.4 
28 C1QBP 708 Complement component 1 Q subcomponent-binding 
protein 
Antibacterial response protein 
complement component 
Mitochondrion matrix; Nucleus -0.3 4.3 
29 NFKB1 4790 Nuclear factor NF-kappa-B p105 subunit Transcription factor Nucleus; Cytoplasm -0.7 4.3 
30 SYT6 148281 Synaptotagmin-6 Membrane trafficking regula-
tory protein 
 Cytoplasmic vesicle 0.5 4.2 
31 BET1 10282 BET1 homolog SNARE protein Golgi apparatus membrane 0.7 4.1 
32 DULLARD 23399 CTD nuclear envelope phosphatase 1 Serine/threonine protein 
phosphatase 
Endoplasmic reticulum membrane -0.7 3.9 
33 DUSP26 78986 Dual specificity protein phosphatase 26 Protein phosphatase Cytoplasm; Nucleus; Golgi appa-
ratus 
-0.5 3.8 
34 PLEK 5341 Pleckstrin Cytoskeletal protein n.a. -0.6 3.5 
35 PLXNC1 10154 Plexin-C1 Tyrosine protein kinase recep-
tor, Protein kinase 
Membrane -0.3 3.4 
36 CHCHD2 51142 Coiled-coil-helix-coiled-coil-helix domain-containing 
protein 2, mitochondrial 
n.a. Mitochondrion 0.0 3.3 
37 SLC1A5 6510 Neutral amino acid transporter B(0) Cation transporter Membrane -0.4 3.1 
38 SLC16A7 9194 Monocarboxylate transporter 2 Transporter Membrane -0.5 3.1 
P150 targets       
39 ATF3 467 Cyclic AMP-dependent transcription factor ATF-3 CREB transcription factor Nucleus 3.9 11.7 
40 RHES 23551 GTP-binding protein Rhes Small GTPase Cell membrane; Lipid-anchor 3.3 9.3 
41 CKM 1158 Creatine kinase M-type Amino acid kinase Cytoplasm.  0.0 7.0 
42 APOA1 335 Apolipoprotein A-I Transporter Secreted 2.0 6.4 
43 TMEM140 55281 Transmembrane protein 140 n.a. Membrane -0.1 6.0 
44 PPIL5 122769 Leucine-rich repeat protein 1 Growth factor receptor, adenyl-
ate cyclase 
n.a. 0.0 5.6 
45 B3GNT1 11041 N-acetyllactosaminide be-
ta-1,3-N-acetylglucosaminyltransferase 
Glycosyltransferase Golgi apparatus membrane 1.8 5.6 
46 POP4 10775 Ribonuclease P protein subunit p29 Endoribonuclease Nucleus 1.8 5.5 
47 SDCCAG3 10807 Serologically defined colon cancer antigen 3 n.a. Cytoplasm 1.6 5.1 
48 SSX4B 548313 Protein SSX4 Transcription factor n.a. 1.2 4.1 
49 KIAA1310 55683 KAT8 regulatory NSL complex subunit 3 n.a. Nucleus 0.9 4.0 
50 IFNA13 3447 Interferon alpha-1/13 Interferon superfamily Secreted 0.4 3.9 
51 CELA2B 51032 Chymotrypsin-like elastase family member 2B Serine protease Secreted 0.4 3.5 
52 ARL8A 127829 ADP-ribosylation factor-like protein 8A Small GTPase Late endosome membrane; Lyso-
some membrane 
0.2 3.4 
53 SNIP1 79753 Smad nuclear-interacting protein 1 Transporter Nucleus 0.2 3.4 
54 EIF4A1 1973 Eukaryotic initiation factor 4A-I RNA helicase, translation initia-
tion factor helicase 
n.a. 0.7 3.3 
55 SULF2 55959 Extracellular sulfatase Sulf-2 Hydrolase Endoplasmic reticulum  0.4 3.3 
56 MRPL54 116541 39S ribosomal protein L54, mitochondrial n.a. Mitochondrion 0.1 3.2 
*n.a.: not available. 
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Figure 4. Rubella virus – host interactions. (A) The representative images show the host target identified for rubella virus using NAPPA arrays displaying 10,000 human proteins. 
The color of the microarray spot from blue to red corresponds to the fluorescent signal from weak to strong. (B) Rubella virus - host interaction network. The host proteins with 
red letters are the previous known targets and solid lines indicate independent validation. The annotation of biological process was performed by the PANTHER (Protein 
ANalysis THrough Evolutionary Relationships) Classification System. The interaction network was constructed with Cytoscape. (C) Selective validation of host targets using 
bead-based pull-down assays. PD: Pull-down, WB: Western blot. Halo protein is used as a query control in both microarray and pull-down assays.  
 
Figure 5. Co-localization analysis of rubella virus capsid and its host targets in HeLa cells. The co-transfection of HeLa cells were executed for 20 hrs using the constructs of 
mChery tagged capsid (Red) and GFP tagged host targets (Green). The cells were fixed in 4% paraformaldehyde and imaged using confocal fluorescence microscopy. The nucleus 
was stained with Hoechst dye and shown as blue. Scale bar, 5µm. 
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Host serological response to coxsackievirus 
proteins 
As a member of Enterovirus family, Cox-
sackievirus B4 is one of the six serotypes of cox-
sackievirus group B. The coxsackievirus B infection is 
common in the summer and autumn in the areas of 
temperate climates and all year in tropics. Adoles-
cents less than 16 years old are the susceptible popu-
lation, but infection has been also observed in adults 
[56]. To investigate whether coxsackievirus proteins 
can serve as antigens inducing a humoral response in 
the blood of people with potential coxsackievirus in-
fection, we performed a serological test using mi-
cro-fluidic multiplexed immunoassays. The experi-
mental setup is shown in Figure 6A. First, we coated 
11 micro-fluidic channels with unpurified HeLa cell 
lysate expressing each of 10 coxsackievirus antigens, 
and one with HeLa cell lysate alone as negative con-
trol (n.c). The immobilization of these antigens (rows) 
was confirmed using anti-Halo tag antibody (col-
umns). These results indicate that all 10 antigens were 
successfully coated on their corresponding channels 
and are observed as specific red fluorescent signals, 
which do not exist in the channel coated with only 
HeLa lysates (n.c.) (Figure 6B). Further signal quanti-
fication shows that the signal intensity of coated cox-
sackievirus antigens is higher than that of the negative 
control plus three folds of the standard deviations 
with an average variation of 26.3% (Figure 6C).  
To detect the serological antibodies, we 
randomly selected 11 sera samples regardless of their 
disease background. The prepared antigen array was 
incubated using 5 µL of 1:10 diluted human serum in 
each channel and the detection was performed using 
an Alexa647 labeled anti-human IgG secondary 
antibody. VP1 and VP0 showed responses in the 
largest number of subjects, each showing responses in 
50% of the subjects; although, VP1 had the strongest 
signal intensity (Figure 6D). Notably, there was not 
complete overlap in the responses to these two 
antigens, with some subjects responding to one but 
not the other. We did not observe any signal in the n.c. 
from either antigens or sera samples (#00), which 
demonstrate the specificity of these antibodies. The 
separation between VP0 and VP1 responders was 
illustrated by performing a two-way non-hierarchical 
cluster analysis and populating a heat-map (Figure 
6E). Most of antigens (VP3, 2C, 2A, VP4, 3C and RP) 
did not show any response in these sera samples. The 
immune-dominant antigens of VP0 and VP1 were 
further validated using ELISA with the same sera 
samples (Figure 6F). Without clinical histories and 
with such a small sample size, we cannot draw 
specific conclusions regarding immunoproteomic 
responses to coxsackievirus B infections. 
Nevertheless, these data illustrate the rapid feasibility 
of using a microfluidic approach to address this 
question. 
Discussion 
During the past decade we have developed a HT 
cloning and management pipeline, which integrates 
customized software, databases, and state-of-art 
robotics (Figure 1). More specifically, the FLEXGene 
database is used to track the overall cloning pipeline 
starting from the uploading of reference sequences, 
through transferring ORFs into the Gateway® entry 
vector and destination vectors, sequence verification, 
preparation of glycerol stock, to the end with the 
submission of final information and plasmid samples 
to DNASU [17, 18]. ACE automates the sequence 
evaluation process, enabling the management of 
hundreds of clones simultaneously by interacting 
with FLEXGene and comparing each clone’s actual 
and reference sequences using defined criteria to find 
discrepancies [20, 21, 46]. DNASU is a central 
repository of plasmids which stores over 200,000 
plasmids from more than ~800 organisms [10, 14]. 
These plasmids are easily searchable through the 
website http://dnasu.org, and DNASU operations 
distribute these plasmids to researchers worldwide 
upon request. Each plasmid is stored in a 2-D 
barcoded tube as a glycerol stock in a fully automated 
-80°C Brooks Biostore freezer allowing fast retrieval 
upon ordering. These collections have demonstrated 
their great value in numerous biological studies in 
basic research, cancer, autoimmune and infectious 
disease [26, 27, 31, 34, 35, 52, 53, 57-60].  
 In this work, we have integrated viral cloning 
into the pipeline that has already been extensively 
used for human and bacterial gene cloning. The 
difference from previous non-viral cloning is that we 
employ gene synthesis for those viral ORFs without 
templates, or whose reference polypeptide sequence 
is not contiguous in the genome (Table 2). The cost of 
gene synthesis is much higher than the 2-step 
PCR-based approach because of the high cost of the 
oligos required for synthesis. Even with local 
synthesis of the oligos using an oligo synthesizer, 
which would reduce the cost, this method is likely to 
be more expensive than the PCR approach. By using 
the GeneDesign 3.0 and the protocol we developed, 
we successfully obtained 100% of the genes we 
attempted to synthesize, with DNA lengths ranging 
from 200 bp to 3,000 bp (Figure 2B).  
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Figure 6. Immunological profiling of human serological response to coxsackievirus antigens. (A) The work flow of micro-fluidic multiplexed immunoassays, (B) The fluorescent 
image of coxsackievirus protein expression and detection using anti-Halo antibody, (C) The fluorescent signal intensity of viral proteins coated in the antigen channels (left, y-axis) 
and the coefficient variations from channel to channel (right, y-axis), (D) and (E) are the fluorescent images and the heatmap of serological antibody profiling using micro-fluidic 
multiplexed immunoassays, respectively. 00 is buffer alone and 01-11 are the human sera samples. n.c. is HeLa cell lysate as negative control, and (F) is the validation of 
immune-dominant antigens (VP0 and VP1) using RAPID-ELISA. 
 
The successful translation of these viral clones to 
proteins is the key to study virus-host interactions, as 
well as their association with human diseases [2]. To 
illustrate this approach, we chose three viruses, two 
(HCMV and rubella virus) with complete ORFeomes 
and one (coxsackievirus) with 10/12 of ORFeome 
clones. We tested this virus-host interaction using a 
human HeLa cell lysate-based cell-free expression 
system. We selected this human cell-free expression 
system because of its inherent advantages of high 
efficiency and effectiveness, and its ability to produce 
membrane and large size proteins [61, 62]. It has been 
recently employed in our lab in the fabrication of 
high-density NAPPA arrays [62, 63]. With this system, 
we found 96.4% HCMV and 100% of rubella virus and 
coxsackievirus ORFeomes were successful expressed 
(Figure 3B, Additional file 1: Figure S1, Figure S3 and 
Table S1). This corresponds favorably to the previous 
results using wheat-germ and rabbit reticulocyte 
lysate cell-free expression systems [52, 64]. These 
results demonstrate the ease and efficiency of our 
viral collection in the production of viral proteins by 
combination with human cell-free expression system 
in vitro.  
The comprehensive collection of viral ORFeome 
clones enables us to study virus-host interaction from 
a systematic standpoint, and reveals new host cellular 
proteins that might be hijacked by viruses to alter host 
cellular processes. Rubella virus is the causative agent 
of German measles in children and congenital rubella 
syndrome when the virus infection occurs during the 
first trimester of pregnancy. In addition, it can cause 
polyarthralgia, a complication of rubella infection in 
adult women. Humans are the only known host of 
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rubella virus, and the development of effective 
vaccines have significantly reduced the incidence in 
developed countries [65]. However, the molecular 
mechanisms of rubella infection/replication in the 
host, and the causation of congenital rubella 
syndrome are still unclear. There have been a few host 
proteins, C1QBP/p32, Bax and RABP, identified to be 
involved in host-rubella interactions [55, 66-68]. In 
this work, we screened all rubella viral proteins on 
NAPPA arrays with 10,000 human proteins, and 
identified 55 novel candidate host targets in addition 
to the three previously identified interactors [66-68]. 
Six viral proteins were selected and validated using in 
vitro based pull-down, and four viral proteins were 
used in in vivo based cellular co-localization analysis 
(Figure 4C and Figure 5). In our intracellular 
localization studies, we found that the rubella 
proteins locate to different sub-cellular locations (i.e. 
membrane (36%), nucleus (19%), cytoplasm (16%), 
secreted (5%), mitochondrion (3%), endoplasmic 
reticulum (2%) and others (14%)) (Figure 4B, 
Additional file 1: Figure S2 and Table 3).  
With all of these identified targets, we 
constructed the first systematic rubella virus-host 
interaction network, and analyzed the biological 
processes of these host targets associated in host cell 
(Figure 4B). The annotation results indicate that four 
capsid targets, C1QBP, Bax, RSF1 and NFKB1, and 
two P150 targets, ATF3 and IFNA13, are involved in 
apoptosis, which is consistent with the cytotoxicity 
caused by rubella virus [68, 69]. Other host targets of 
E1, E2, capsid and P150 are associated with transport, 
transcription/translation and metabolic processes. 
P90 has the fewest targets associated with metabolic 
processes [55, 70]. 
E1 is the main surface viral protein that might 
co-opt the host G-protein-coupled receptors and 
activate their downstream pathways through GPR1 
and GRP62 [71, 72]. The functions of E2 and P90 are 
largely unknown; although, it was found that the 
glycosylation of E2 could alter the specific membrane 
fusion using rubella virus JR23 strain [73]. Here, we 
provide new evidence that E2 and P90 may 
participate in the viral attachment and fusion between 
viral envelope and the endosomal membrane through 
membrane proteins of GNAZ, TMEM106B and 
GPR27, and regulate the cytoskeleton by RhoJ [72, 74]. 
In addition, E2 and P150 may be involved in the viral 
vesicle transportation through Rab and Arl GTPases 
of Rab25 and Arl8A [75, 76]. Viral capsid is the only 
protein that has been found with multi-functions, 
which include the regulation of viral replication and 
acting as a potent inhibitor of host cell apoptosis and 
protein synthesis [55, 66, 68]. Here we found, besides 
C1QBP, that the capsid may also interact with other 
host cell proteins in membranes, cytoplasm, 
mitochondria, endoplasmic reticulum, Golgi, and 
nucleus, and can include such host proteins as 
PLXNC1, CHCHD2, BET1, NFKB1, etc. [77, 78]. These 
results need additional confirmation with cell-based 
in vivo assays; however, these results give us a first 
glimpse of a comprehensive view of rubella-virus 
interactions by physical interactions. In future 
functional studies, these results may reveal important 
host proteins involved in the regulation of rubella 
viral invasion, transportation, and replication. 
Most of coxsackievirus B4 infection exists as 
asymptomatic, undifferentiated febrile illness, or mild 
upper respiratory symptoms. But this virus can 
induce a wide range of diseases such as aseptic 
meningitis, encephalitis, pleurodynia, myocarditis, 
and pericarditis [79-82]. The development of a rapid 
serological test and vaccine would be a valuable tool 
in the early diagnosis and prevention of 
coxsackievirus [83]. In this work, we tested the 
antigenicity of coxsackievirus proteins using a 
micro-fluidic multiplexed immunoassay which can 
detect up to 24 antigens simultaneously with only 0.5 
µL undiluted human serum [42]. We found the 
unpurified coxsackievirus proteins in HeLa cell 
lysates can be coated on the amino modified slide 
surface and detected with anti-Halo tag antibody 
(Figure 6B and 6C). The uses of unpurified cell-free 
produced proteins have been frequently employed in 
the fabrication of pathogen microarrays to screen and 
validate antibody biomarkers of infectious diseases 
[84-87]. The key step of this approach is to block the 
non-specific bindings of serum antibodies to 
background proteins originating from HeLa cell 
lysates or E.coli during DNA preparation [88]. Here, 
we found by blocking the sera using a mix of HeLa 
cell and E.coli lysates in 5% milk, the background was 
largely decreased and the signal to noise ratio was 
improved. The screening of 11 sera samples using 
microfluidic multiplexed immunoassay and ELISA, 
revealed that VP0 and VP1 might be two dominant 
antigens which are recognized by the host immune 
system (Figure 6D-F). The differential antigenicity of 
VP0 and VP1 implies that these two antigens might be 
potential markers that have complementary value in 
the diagnostics of coxsackievirus infection as well as 
development of a new vaccine. However, further 
experiments with much larger well-characterized 
clinical sample sets are needed to establish this 
relationship.  
Conclusion  
In this work, we describe the initial effort of our 
panviral proteome with the collection of 2,035 viral 
OFR clones from 30 viral species. We demonstrated 
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the uses of our viral collection in the highly efficient 
production of viral proteins using cell-free expression 
system in vitro, global identification of host targets for 
rubella virus using NAPPA protein arrays, and 
detection of host serological response using 
micro-fluidic multiplexed immunoassays. In the 
future, we will be continuing to collaborate with other 
labs to extend our collection, study viral 
invasion/evasion mechanisms, develop novel 
diagnostic tools, and drugs for the therapeutic 
treatment. 
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Supplementary methods, Figure S1-S3 and Table S1. 
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